AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Schrödinger vs Recursion Pharmaceuticals

VS
Schrödinger official logo and brand icon

Schrödinger

Enterprise
Visit WebsiteFull Review
Recursion Pharmaceuticals official logo and brand icon

Recursion Pharmaceuticals

Enterprise
Visit WebsiteFull Review

Verdict by Category

Detailed category analysis is not available for this comparison.
View Schrödinger View Recursion Pharmaceuticals
Feature & Spec Matrix

Detailed Comparison25 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
Schrödinger
Schrödinger
Recursion Pharmaceuticals
Recursion Pharmaceuticals
Pricing Model
EnterprisePhysics-based molecular modeling & drug discovery suite — Academic site licenses & commercial enterprise quotes on sales consultation
EnterpriseAI-enabled drug discovery and mapping (Recursion OS) — Custom biopharma enterprise partnership agreements only
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
Academic licensing available at reduced rates; commercial pricing via sales team
No self-serve access — enterprise pharma collaborations and data licensing via partnership team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical scientists and computational chemists needing physics-based molecular simulation for drug discovery, lead optimization, and ADMET prediction
Major pharma companies and researchers needing AI-powered biology mapping, target discovery, and drug candidate generation at industrial scale through the Recursion OS platform
Enterprise & Scalability
Difference
NASDAQ listed (SDGR), enterprise software licensing with volume pricing, cloud-hosted subscriptions, strategic research collaborations with BMS, Sanofi, and Takeda, dedicated scientific support teams, and academic/government licensing programs
NASDAQ listed (RXRX), $500M+ in pharma partnership milestones earned, enterprise collaboration agreements with Roche/Genentech and Sanofi, automated biology and chemistry labs at industrial scale in Salt Lake City and Oxford, and data licensing for external researchers
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Physics-based molecular simulation: Maestro, Glide, Jaguar, Prime, and FEP+ for drug and materials discovery
Supported
Supported
Bunsen AI co-scientist (July 2026) for hypothesis generation, experiment design, and molecular insight
Difference
Schrödinger Advantage
Not listed
FEP+ for industry-leading binding affinity prediction in lead optimization
Difference
Schrödinger Advantage
Not listed
Structure-based drug design, ADMET prediction, and quantum chemistry in one platform
Difference
Schrödinger Advantage
Not listed
Cloud-hosted software subscriptions with 10-15% ACV growth target for 2026
Difference
Schrödinger Advantage
Not listed
Drug discovery pipeline with BMS, Sanofi, and Takeda — FY26 guidance raised to $65-75M
Difference
Schrödinger Advantage
Not listed
Materials science applications: battery design, semiconductors, and specialty chemicals
Difference
Schrödinger Advantage
Not listed
$255.87M revenue in 2025 with 23% growth — NASDAQ listed (SDGR)
Supported
Supported
500+ enterprise customers including top 20 global pharma companies
Difference
Schrödinger Advantage
Not listed
Founded 1990 by Professor Richard Friesner — 34+ years of computational chemistry leadership
Difference
Schrödinger Advantage
Not listed
Industrial-scale automated labs in Salt Lake City and Oxford generating proprietary multimodal data
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-4881 for FAP — 53% polyp reduction in Phase 2, FDA registration discussions begun 2026
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-1245 (RBM39 degrader) in Phase 1/2 DAHLIA study for solid tumors
Difference
Not listed
Recursion Pharmaceuticals Advantage
REC-4539 (LSD1 inhibitor) — first patient dosed in Phase 1 ENLYGHT study 2026
Difference
Not listed
Recursion Pharmaceuticals Advantage
Sanofi partnership — $134M earned to date across 5 milestones
Difference
Not listed
Recursion Pharmaceuticals Advantage
Roche/Genentech Phenomaps — 1 trillion neuronal cells for neuroscience target discovery
Difference
Not listed
Recursion Pharmaceuticals Advantage
$500M+ in cumulative pharma partnership milestones earned to date
Difference
Not listed
Recursion Pharmaceuticals Advantage
Recursion Data — phenomics and biology maps licensed to external researchers and pharma
Difference
Not listed
Recursion Pharmaceuticals Advantage
Schrödinger icon

Schrödinger Pros & Cons

Pros

  • 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
  • Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
  • FEP+ delivers industry-leading accuracy in binding affinity prediction
  • NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
  • 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
  • Materials science applications extend reach to battery, semiconductor, and chemical sectors
  • Cloud-hosted subscriptions eliminate on-premise infrastructure burden

Cons

  • Software is expensive — enterprise pricing puts it out of reach for smaller labs
  • Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
  • Drug discovery segment revenue is milestone-dependent and lumpy
  • Platform learning curve is steep without computational chemistry background
  • Competition from newer, purely AI-native platforms is intensifying
Recursion Pharmaceuticals icon

Recursion Pharmaceuticals Pros & Cons

Pros

  • $500M+ in pharma partnership milestones — most validated AI drug platform by commercial revenue
  • Recursion OS is the most vertically integrated AI drug discovery system — biology to clinic in one platform
  • Industrial-scale automated labs generate data no other company can replicate
  • Phase 2 FAP clinical proof of concept — 53% polyp reduction — FDA registration discussions began
  • Roche/Genentech and Sanofi as partners — two of the world's top 5 pharma companies
  • Exscientia acquisition in 2024 added cutting-edge small molecule AI design capabilities
  • Cash runway guided into early 2028 — disciplined capital allocation

Cons

  • Stock (RXRX) is below $5 — significant market skepticism on timeline to commercial drugs
  • Operating cash burn of ~$390M in 2026 — needs continued capital or milestone payments
  • Acquired Exscientia in 2024 — integration complexity and added operational overhead
  • No approved drugs yet — clinical proof of concept still early stage
  • Proprietary platform requires industrial-scale automation infrastructure that can't be self-built
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Recursion Pharmaceuticals vs Insilico Medicine Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Insilico Medicine in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Schrödinger vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Schrödinger and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Recursion Pharmaceuticals vs Suki AI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Recursion Pharmaceuticals and Suki AI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Google NotebookLM vs Obsidian Comparison Battle Card - Features, Pricing & Review in AI Research Synthesis & Personal Knowledge Management
Direct head-to-head AI tool comparison between Google NotebookLM and Obsidian in AI Research Synthesis & Personal Knowledge Management featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Research Synthesis & Personal Knowledge ManagementCompare